Phaseline

Targets › IFNAR2

IFNAR2 (Interferon alpha/beta receptor 2): drug programs, companies and trials

7 programs from 7 companies in 25 trials: 13 Phase 2, 6 Phase 3, 4 Phase 1, 2 Phase 4; Oncology, Infectious disease, Neurology; next expected readout Mar 2027.

Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. (UniProt, P48551)

Open in Phaseline: the race on IFNAR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PharmaEssentiaRopeginterferon Alfa-2B (P1101)
Interferon alpha/beta receptor positive modulator
IFNAR1, IFNAR2Phase 3Polycythemia Vera; Primary Myelofibrosis; Essential Thrombocythemia; Primary Myelofibrosis (PMF) …Mar 2027
BiogenPeginterferon Beta-1A (BIIB017)
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 3Multiple Sclerosis, Relapsing-RemittingMay 2027
BriaCell TherapeuticsInterferon Alfa-2B
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 3Breast Cancer; Colorectal Neuroendocrine Tumor G1; Prostate Adenocarcinoma; Polycythemia VeraDec 2027
Xiamen Amoytop BiotechPeginterferon Alfa-2B
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2Essential Thrombocythemia; Hepatitis B, Chronic; Malignant MelanomaSep 2027
Brii BiosciencesPeginterferon Alfa-2A
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) Infection; Chronic Hepatitis b; Chronic Hepatitis BSep 2028
Diakonos OncologyPeginterferon Alfa-2A
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2Glioblastoma (GBM)Mar 2030
M.D. Anderson Cancer CenterRecombinant Interferon Alpha 2b-like Protein
Type I interferon receptor agonist
IFNAR1, IFNAR2Phase 1Stage III Hepatocellular Carcinoma AJCC v8Feb 2028

Conditions

Polycythemia Vera (3) Essential Thrombocythemia (3) Chronic Hepatitis b (2) Glioblastoma (GBM) (1) Primary Myelofibrosis (1) Primary Myelofibrosis (PMF) (1) Chronic Myeloid Leukemia (1) Cutaneous T Cell Lymphoma (1) Ropeginterferon (1) Myelofibrosis (1) Breast Cancer (1) Colorectal Neuroendocrine Tumor G1 (1)

Modalities

mixed (4), protein or peptide (3)

Companies

Diakonos Oncology (1) PharmaEssentia (1) BriaCell Therapeutics (1) Brii Biosciences (1) Xiamen Amoytop Biotech (1) Biogen (1) M.D. Anderson Cancer Center (1)

Related targets

IFNAR1 (7)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.